TNF Pharmaceuticals Improves Its Financial Position Over The Past 5 Months Through A Material Reduction In Liabilities, While Maintaining Total Assets Of Over $17M As Of June 30, 2025

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025.

"The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities," said TNF President and Chief Medical Officer, Mitchell Glass, M.D. "We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF's business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage."

The improvements in the Company's financial position will be reflected in future financial statements of the Company.